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Abstract
High proportion of human embryos produced by in vitro fertilization (IVF) are 
aneuploidy or have segmental chromosomal errors. Not only a whole chromosome 
aneuploidy, but also small errors in a chromosome, such as microdeletion can be 
detected by current next-generation sequencing (NGS) for preimplantation genetic 
testing (PGT). The prevalence of aneuploidy in donor egg IVF was significantly 
different between fertility clinics. In the present study, we examined whether dif-
ferent embryo biopsy procedures affect embryonic aneuploidies in donor egg IVF. 
We did not find significant differences in the samples with abnormal chromosomes 
between two biopsy methods. When we further analyzed the samples with abnor-
mal chromosomes, we found that 64.0–80.7% of the abnormalities were whole 
chromosome aneuploidies while 19.3–36.0% were segmental chromosome abnor-
malities. High embryo implantation rates were obtained after transferring screened 
euploid blastocysts. These results indicate that blastocyst biopsy procedures may 
not significantly affect embryo’s chromosomal status, but PGT by high-resolution 
NGS revealed that high proportions of human embryos derived from donor eggs are 
not only aneuploidy, but also segmental chromosome abnormal, and screening of 
small chromosomal errors by NGS is beneficial to patients who use donated eggs for 
infertility treatment.
Keywords: aneuploidy, blastocyst, donor eggs, human, in vitro fertilization, 
preimplantation genetic testing, segmental chromosome abnormalities
1. Introduction
Embryonic aneuploidy in human in vitro fertilization (IVF) is very common 
and is one of the factors reducing embryo implantation and causing birth defects. 
Although aneuploidy is mainly observed in the embryos from patients with advanced 
maternal ages [1–3], it is also very common in the embryos from young patients and 
oocyte donors [4–9]. The frequencies of aneuploid embryos produced by IVF have 
been widely studied [4–12] by examination of all chromosomes with microarray and 
next generation of sequencing (NGS) through preimplantation genetic testing for 
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aneuploidies (PGT-A) [13–17]. With PGT-A by NGS, not only a whole chromosome 
aneuploidy can be detected, but also segmental chromosome abnormalities (deletion 
and duplication) can be detected [18–21]. Segmental chromosome abnormalities 
typically represent regional losses or gains in one or more chromosomes. The size of 
a segmental abnormalities detectable by current NGS platforms is as small as 1 Mb, 
however, for PGT-A, usually 10 Mb and above are detected and reported.
Some segmental chromosome abnormalities may cause miscarriage and birth 
defect, while others may result in developmental delay and/or intellectual dis-
ability if the transfer of such embryos produce live birth. It has been found that 
the prevalence of embryonic aneuploidy in donor egg IVF was significantly dif-
ferent between fertility clinics indicating that clinical and laboratory procedures 
may be related to the occurrence of embryonic aneuploidies [12]. Embryo biopsy 
is a complicated and invasive laboratory procedure that involves several embryo 
manipulations during culture, so it may affect embryo’s quality including aneuploi-
dies. Therefore, in the present study, to examine whether embryo biopsy procedures 
affect embryonic aneuploidies in donor egg IVF, blastocysts were biopsied by two 
different biopsy methods and then the samples were examined by NGS. Collected 
data were analyzed in terms of the rates of embryos with whole chromosome 
aneuploidies and segmental chromosome abnormalities. Clinical outcomes, such as 
pregnant rate, live birth rate and embryo implantation rate were also analyzed.
2. Materials and methods
2.1 Ethical statement
The patients signed the consents for all laboratory and clinical procedures 
including embryo biopsy for PGT-A. The data was collected from medical records at 
the clinic and laboratory, and the study with PGT-A was approved by New England 
Institutional Review Board (NEIRB 14–504).
2.2 Donor stimulation
Donors for IVF treatment underwent controlled ovarian stimulation with a 
combination of daily injection of 75–300 IU recombinant follicle-stimulating hor-
mone (Gonal-F, EMD Serono, MA, USA) and 75–300 IU of a combination of follicle 
stimulating hormone and luteinizing hormone (Menopur, Ferring Pharmaceuticals, 
NJ, USA). On day 5–7, 0.25 mg gonadotropin releasing hormone antagonist 
(Cetrotide, EMD Serono) was given daily until triggering for oocyte maturation by 
gonadotropin-releasing hormone agonist (Lupron) or human chorionic gonado-
tropin (hCG). Oocytes were retrieved at 35–36 hours after the trigger and then 
cultured in Global™Total medium (Origio Inc., CT, USA) at 37°C in an atmosphere 
of 5.5% CO2, 6% O2, and balanced N2 under humidified or dry conditions.
2.3 Oocyte insemination and embryo culture
Oocytes were inseminated by intracytoplasmic sperm injection (ICSI) after cumu-
lus cells were removed by using hyaluronidase (Fujifilm-Irvine Scientific) at 3–4 hours 
after oocyte retrieval and metaphase II oocytes were injected 4–5 hours after retrieval. 
After insemination, oocytes were cultured in Global™Total medium at 37°C in an 
atmosphere of 5.5% CO2, 6% O2, and balanced N2 under humidified or dry conditions.
Fertilization was assessed 16–18 hours after insemination, and normal fertiliza-
tion was characterized by two distinct pronuclei and two polar bodies. Fertilized 
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oocytes were further cultured in the Global™Total medium and embryo quality was 
evaluated by an inverted microscope on day 3, 5, or 6.
2.4 Blastocyst biopsy
Two biopsy methods were used in the present study. The first is a traditional 
two-step method in which a small hole in zona pellucida was opened by laser pulses 
on cleavage embryos at Day 3. As shown in Figure 1, when embryo developed to 
blastocyst at day 5 or later and some cells from blastocysts hatched from the hole, 
5–10 cells were aspirated to a biopsy pipette and then cells were separated from 
blastocyst proper by mechanical pulling and laser pulses.
The second is a modified and simplified one-step method with less embryo 
manipulation and less laser application. Hole opening in the zona pellucida was 
not performed on day 3 embryos. Blastocysts were directly processed for biopsy. 
The details for this method are as the follows: As shown in Figure 2, blastocyst for 
biopsy was held to a proper position (Figure 2A) in which inner cell mass (ICM) 
was on the 6–9 O’clock position, a small hole in the zona pellucida was opened 
(Figure 2B) on the 3 O’clock position by one laser pulse with the ZILOS-tk™ laser 
system (Hamilton Thorn Bioscience Inc., MA, USA). A 20 μm polished biopsy 
pipette (Sunlight Medical, Jacksonville, FL, USA) was inserted to inside zona pel-
lucida through the hole and a few trophectoderm cells on the 12–2 O’clock position 
were aspired into biopsy pipette (Figure 2B). After biopsy pipette was pulled out of 
the zona (Figure 2C), biopsy pipette together with blastocyst was moved to the top 
the holding pipette (Figure 2D), and the biopsy pipette was pull down against the 
holding pipette so that the cells inside the biopsy pipette were completely separated 
from blastocyst proper (Figure 2E).
After biopsy, biopsied cells were washed individually, transferred to PCR tubes, 
and stored at −20°C freezer until processing for PGT-A by commercial genetic 
testing company. Blastocysts were individually cryopreserved by vitrification for 
later frozen embryo transfer (FET). Blastocysts were classified as abnormal if they 
Figure 1. 
Procedures for two-step blastocyst biopsy. A blastocyst with some trophectoderm cells being hatched from the 
hole in the zona pellucida opened on day 3 and the blastocyst is held to a proper position for biopsy (A). After a 
few trophectoderm cells are aspirated into biopsy pipette, one laser pulse is applied on upside of the cells  
(B) and another lase pulse is applied to the bottom side of cells (C) during mechanical pulling. Extra laser 
pulses may be necessary during pulling until the cells are completely isolated from blastocyst proper (D).
Cytogenetics - Classical and Molecular Strategies for Analysing Heredity Material
4
had any chromosomal error(s). The abnormal samples were further divided into 
aneuploidy if they had gain and/or missing of a chromosome(s) and segmental 
abnormal if they had only deletion and/or duplication in a chromosome(s).
Figure 2. 
Procedures for one-step blastocyst biopsy. A blastocyst is held to a proper position for biopsy and a small hole is 
opened in the zona by a laser pulse at 3 O’clock position (A). A biopsy pipette is inserted into the zona through 
the hole and a few trophectoderm cells are aspirated into biopsy pipette after blastocyst is collapsed or during 
collapsing from 12 to 2 O’clock position (B). Biopsy pipette is pull out of the zona (C) and the biopsy pipette 
together with blastocyst is moved to the top front of holding pipette (D). Biopsy pipette is pull down against 
the holding pipette to cut the cell connection between blastocyst proper and aspirated cells at the tip of biopsy 
pipette (E).
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2.5 Blastocyst vitrification, warming and transfer
Blastocysts were vitrified using a vitrification device (Cryotop, Vitristraw or 
Mini straw) and kit (Fujifilm-Irvine Scientific, Irvine, CA, USA). Both equilibra-
tion solution and vitrification solution were warmed in original vials at 37°C for at 
least 30 min before use. Briefly, collapsed blastocysts were equilibrated in 100 μl 
drop (without oil cover) of equilibration solution for 2 min, and then 45 seconds in 
100 μl drop (without oil cover) of vitrification solution (both steps were performed 
on a 37°C warming stage) before loading to vitrification device. All blastocysts were 
vitrified individually and then stored in liquid nitrogen until warming for FET.
For warming, blastocysts were exposed to a thawing solution (Fujifilm-Irvine 
warming kit) at 37°C for 1 min, transferred to a dilution solution for 3 min and 
finally to a washing solution for 10 min with a solution change after 5 min at room 
temperature. After completion of the warming process, zona pellucida in the 
blastocysts were further cut by laser pulses to open 1/4–1/5 (2D image size) of zona 
pellucida and then cultured in Global™Total medium for 2–4 h before transfer.
For preparation of the transfer, patients received estradiol (Estrace, Warner 
Chilcott, NJ, USA) orally or vaginally, and estradiol patch (Estradiol Transdermal 
System, Noven Pharmaceuticals, NJ, USA) every three days, as well as progesterone 
that was administered on 15th day of estradiol treatment. Blastocysts were trans-
ferred on the sixth or seventh day of progesterone administered, and progesterone 
was continued daily until the first serum β-hCG test two weeks after transfer. 
Ongoing pregnancy was supported by continued estradiol and progesterone until 
11 weeks of pregnancy. Pregnancy was initially confirmed 14 days after embryo 
transfer by a serum β-hCG assay. Four weeks after embryo transfer, when a gesta-
tional sac and a heartbeat appeared, the patient was diagnosed as having a clinical 
pregnancy. Live birth rates were calculated based on the number of live birth and 
number of transfers.
2.6 Statistical analysis
Interval data was analyzed by one-way analysis of ANOVA. The differences 
between groups were compared with chi square test. If the P value was less 0.05, the 
difference was considered to be statistically significant.
3. Results
To examine whether day 3 zona hole opening by laser pulse affected embryo 
development, blastocyst development between embryos with or without this pro-
cedure were compared. As shown in Table 1, similar blastocyst development rates 
(64.7 vs. 64.3%) were observed between two groups. Other parameters, such as egg 
donor’s ages (26.5 ± 3.0 vs. 25.6 ± 2.6), and fertilization rates (86.4 vs. 88.8%) were 
also similar between two groups.
As shown in Table 2, after biopsy, the proportions of samples without tested 
results due to low quantity of DNA or no DNA in the samples were similar between 
two biopsy methods (3.6 vs. 4.4%), resulting in 96.4% of the samples biopsied 
with one-step method and 95.6% of the samples biopsied with two-step method 
were successfully amplified. It was found that euploid blastocyst rates were similar 
between two groups (63.4 vs. 64.0%).
Chromosome abnormalities include whole chromosome aneuploidies (extra 
and/or missing chromosomes), and segmental chromosome abnormalities, such as 
chromosome deletion and duplication. As shown in Table 2, no differences were 
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observed in the samples with whole chromosome aneuploid rates or segmental 
abnormalities between two biopsy methods. Samples with multiple chromosomal 
abnormalities were also similar between two biopsy methods.
One-step method Two-step method P value
# of blastocysts biopsied 527 407 NA
# of samples without test results (%) 19 (3.6) 18 (4.4) 0.53
# of samples with test results (%) 508 (96.4) 389 (95.6) 0.53
# of euploid blastocysts (%) 322 (63.4) 249 (64.0) 0.85
# of embryos with abnormal chromosomes 186 (36.6) 140 (36.0) 0.85
# of aneuploid blastocysts (%) 119 (64.0) 113 (80.7) 0.06
# of segmental abnormalities (%) 67 (36.0) 27 (19.3) 0.06
# of samples with ≥2 abnormal chromosomes 45 (37.8) 50 (44.2) 0.32
NA: Not applicable.
Table 2. 
Comparison of chromosomal abnormalities in the blastocysts after biopsy by one-step and two-step methods.
Zona hole opening at Day 3 embryo
- + P Value
# of cases 61 45 NA
Donor age (Mean ± SD) 26.5 ± 3.0 25.6 ± 2.6 0.45
No. of eggs inseminated 1050 726 NA
No. of eggs fertilized (%) 907 (86.4) 645 (88.8) 0.12
No. of blastocysts (%) 587 (64.7) 415 (64.3) 0.88
NA: Not applicable.
Table 1. 
Development of human embryos with or without laser zona hole opening that was performed on cleavage stage 
embryos at day 3.
Figure 3. 
Distribution of chromosomes in the aneuploid blastocysts biopsied with one-step and two-step method. Data 
represent the number of samples with a single abnormal chromosome and multiple (M: ≥2) abnormal 
chromosomes.
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As shown in Figure 3, aneuploidies occurred in all chromosomes except chro-
mosome 12 and the differences for each chromosome were not statistically signifi-
cant between two methods.
As shown in Table 3, transfer of euploid blastocysts biopsied by one-step method 
had higher chemical pregnancy (78.7 vs. 63.4%), clinical pregnancy (74.5 vs. 61.0%), 
live birth (70.2 vs. 58.5%) and embryo implantation rates (62.7 vs. 49.2%) as com-
pared with transfer of euploid blastocysts biopsied by two-step method. Although 
these rates were not statistically significant between two groups, improved clinical 
outcomes were observed when one-step biopsy method was used.
4. Discussion
Recently Munne et al. found that euploidy rate in human embryos produced by 
donor egg IVF differed significantly between infertility clinics [12], but they did 
not analyze the cause(s) related to these differences. Because they collected data 
from multiple IVF clinics and each clinic used different biopsy methods, which 
may make it difficult to analyze these factors. In the present study, to minimize 
the effects of maternal age-related aneuploidy formation in the embryos [6, 13–15, 
17–20], we also used donor egg IVF cycles to examine whether biopsy methods 
affect embryo aneuploidies. Our data indicate that biopsy methods do not affect 
embryonic aneuploidies, however, simplified biopsy method may improve embryo 
implantation that may be benefited from reduced embryo manipulations and 
limited laser applications. We also found that high proportions of human embryos 
from donor egg IVF are not only whole chromosome aneuploidy, but also have 
segmental chromosome abnormalities.
Although most of embryonic aneuploidies have already occurred before oocyte 
and sperm are collected for IVF due to meiotic error(s) during oocyte and sperm 
development [1–3], some of aneuploidies may be caused by mitotic errors, or 
suboptimal in vitro conditions and/or in vitro manipulations [1]. Rigorous tempera-
ture control during oocyte manipulations can maintain meiotic spindle integrity 
that may prevent meiosis error during final oocyte maturation after egg retrieval 
[1]. While embryo biopsy for PGT-A is still an invasive laboratory procedure, thus 
different methods may affect the embryo quality including chromosome integrity. 
Since laser was used to zona hole opening and blastocyst biopsy in human IVF, it 
has made the biopsy procedure to be easy [21]. However, excess use of laser pulses 
One-step method Two-step method P value
# of transfers 47 41 NA
Mean age of recipients 42.0 ± 6.8 42.9 ± 6.7 0.24
# of chemical pregnancy (%)* 37 (78.7) 26 (63.4) 0.11
# of clinical pregnancy (%)** 35 (74.5) 25 (61.0) 0.18
# of live birth (%) 33 (70.2) 24 (58.5) 0.25
# of blastocysts transferred 59 63 NA





Comparison of clinical outcomes after transfer of euploid blastocysts biopsied by one-step and two-step 
methods from donor egg cycles.
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may be harmful to embryos and eventually would affect embryo development. For 
example, laser pulse(s) are applied on both cleavage embryos and blastocysts for 
the traditional two-step biopsy. The blastomeres next to the laser pulses may have 
different degrees of heat injuring, some injuries can be seen immediately or after 
further culture, while minor injuries may not be able to see under microscope dur-
ing culture. Because the biopsied cells are mostly originated from these cells next to 
the position with laser pulses, chromosomes in some of these cells may be affected, 
which would eventually increase the rates of chromosomal abnormalities. However, 
based on our results observed in the present study, these manipulations of embryos 
do not affect chromosome integrity in the biopsied cells thus the aneuploidies after 
two-step biopsy were not increased as compared with one-step biopsy method. 
These results indicate that the chromosome abnormalities during embryo develop-
ment, if occurs, are not from biopsy procedures.
However, biopsy procedures did affect embryo implantation. Previous studies 
with non-donor egg IVF found that blastocyst rates and live birth rates were reduced 
when day 3 zona opening was performed for two-step biopsy [22, 23]. Although we 
did not find the reduced blastocyst development after day 3 embryo manipulation in 
the present study, both embryo implantation and live birth rates were reduced when 
two-step biopsy procedure was used. These results indicate that laser pulses for zona 
hole opening at day 3 embryos may have detrimental effects on subsequent embryo 
development and embryo implantation ([22, 23], current study). We did not observe 
the differences in the blastocyst development after day 3 embryo manipulation in 
the present study as compared with no day 3 embryo manipulation, which may be 
due to good quality of oocytes from donors as compared oocytes from patients, thus 
some blastomeres might be affected, but overall blastocyst development rate was 
not reduced. Zona hole opening on day 3 embryos by laser pulses may affect embryo 
development especially if the perivitelline space is small or laser power is too large, 
thus the detrimental effects were caused by over-heating from laser pulses.
Although the statistical differences of embryo implantation rates between two 
biopsy methods were not significant due to small cycle numbers in the study by 
Zhao et al. [22] and in our current study, the differences were significant in the study 
by Rubino et al. in which more IVF cycles were examined [23]. When we reviewed 
the clinical outcomes by one-step and two-step biopsy methods in these studies, 
we found that the overall live birth rates could be increased by approximately 10% 
(9.26–12.7%) if one-step biopsy method was used, irrespective of small number of 
cycles or large number of cycles ([22, 23] and the current study) were analyzed.
Another reason for reduced embryo implantation after two-step biopsy may 
be resulted from blastocyst biopsy procedures. The traditional two-step blastocyst 
biopsy is performed by mechanical pulling and laser pulses. Heating from laser 
pulses would also cause injuries to the cells exposed to laser pulses, which would 
negatively affect embryo quality. Our one-step biopsy procedure is similar as that 
reported previously [22–24] but some modifications has been made. Cells were 
aspirated inside zona pellucida that is same as that used by Rubino et al. [23]. 
However, the cells aspirated into biopsy pipette were separated from blastocyst 
proper by mechanical blunt dissection, not by mechanical pulling and laser pulses, 
which is same as that reported by Zhao et al. [24].
The summarized benefits of our method are as the follows: First, one-step 
method does not need to have embryos to be exposed to laser pulse at day 3, which 
has been found to be detrimental to blastocyst development [22, 23]. Second, 
trophectoderm cells are aspirated inside zona pellucida, so that the fertilization of 
oocytes for PGT-A can be performed by either ICSI or regular IVF, and the contami-
nation by cumulus cells or sperm can be minimized and avoided. Third, the separa-
tion of testing cells from blastocyst proper is made by mechanical blunt dissection, 
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not by mechanical suction/pulling and multiple laser pulses, thus the further 
injuries by laser pulses on isolated cells and blastocyst proper can be avoided. And 
the last, ICM may hatch from the hole in some blastocysts if zona opening is done 
at day 3 embryos, thus biopsy need to be done on a different position [23], which 
would further affect embryo’s implantation competence.
A previous study reported monozygotic twins when two-step biopsy was used 
[23]. In the present study, we did not observe any monozygotic twins after transfer 
of blastocysts biopsied by either one-step or two-step method, and this may be 
attributed to the zona cutting (1/4–1/5) in all frozen blastocysts after warming. 
We performed blastocyst vitrification after blastocysts were completely collapsed, 
and the blastocysts were still at collapsed status after warming. The perivitelline 
space was still very wide after warming, thus laser cutting of a large portion of 
zona pellucida did not have any injury to the blastocysts. This procedure may avoid 
monozygotic twins after blastocyst biopsy.
Although biopsy procedures did not affect aneuploid formation in donor egg 
IVF, the proportions of embryos from donor egg IVF with chromosomal abnor-
malities are very high [8, 9, 12, 14, 15]. In the present study, we found that these 
chromosome abnormalities include the whole chromosome aneuploidies and 
segmental chromosome abnormalities. It has been estimated that ~32% of seg-
mental abnormalities are originated from meiosis [25]. However, most segmental 
abnormalities originate from mitosis and are present in a mosaic pattern [25, 26]. It 
has been found that segmental abnormalities can occur in any chromosome, and the 
frequency of deletions and duplications is roughly equal [25].
It has been reported that approximately ~6–15% of blastocysts from human 
IVF have segmental abnormalities when evaluated by current PGT-A methods with 
different analysis platforms [25, 27, 28]. The incidence of blastocysts with only 
segmental abnormalities is about 2.4%–7.5% of all samples examined [25, 27–29]. 
However, in the present study, the segmental chromosome abnormalities accounts 
for approximately 20–40% of the abnormalities, or around 6–12% of all samples 
examined, which were higher than previous reports [25, 27, 28]. These differences 
may be attributed to different PGT analysis platforms because the resolutions and 
accuracies are different between platforms. The high-resolution PGS platforms, 
such as NGS, can detect more small chromosome errors than previous microar-
ray and low-resolution platforms. This may also be explanation that PGT by NGS 
improves pregnancy outcomes compared with array comparative genomic hybrid-
ization in single thawed euploid embryo transfer cycles [16].
It has been reported that the incidence of segmental abnormalities in human 
embryos do not correlate with patient age [25, 27, 28]. This may be the reason that 
high rates were observed in the embryos derived from young and healthy egg 
donors. Transfer of these embryos would result in failed implantation, miscar-
riage, or possibly liveborn congenital syndromes if carried to term [29, 30]. Some 
syndromes and conditions may be related to development delay and intellectual 
disabilities such as 1q21.1 deletion syndrome, 16p11.2 deletion syndrome and 1p36 
deletion syndrome [31], thus screening of these syndromes that have small segmen-
tal chromosome abnormalities may be necessary in human IVF.
5. Conclusions
In conclusion, the outcomes from two previous studies [22, 23] and the current 
study indicate that one-step blastocyst biopsy can improve blastocyst implantation 
rate and live birth rate by ~10% in non-donor IVF patients [22, 23] and donor egg 
IVF patients (current study), suggesting that one-step biopsy method is superior 
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to two-step method. Although blastocyst biopsy procedures may not affect the 
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whole chromosome aneuploidies, buy also segmental abnormal. Therefore, screen-
ing of these chromosome abnormalities may reduce embryo implantation failure, 
early miscarriage, birth defect, developmental delay and/or intellectual disability.
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